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A Ab bs st tr ra ac ct t
Although investigators using methodologies in bioinformatics have always been useful in genomic
experimentation in analytic, engineering, and infrastructure support roles, only recently have
bioinformaticians been able to have a primary scientific role in asking and answering questions on
human health and disease. Here, I argue that this shift in role towards asking questions in
medicine is now the next step needed for the field of bioinformatics. I outline four reasons why
bioinformaticians are newly enabled to drive the questions in primary medical discovery: public
availability of data, intersection of data across experiments, commoditization of methods, and
streamlined validation. I also list four recommendations for bioinformaticians wishing to get more
involved in translational research.
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I In nt tr ro od du uc ct ti io on n
Over the past decade, a large amount of individual-level
molecular data has come from the use of gene expression
microarrays [1,2], proteomics [3], and DNA sequencing
[4,5]. Although high-throughput measurement modalities
such as these have been used in biomedical research for over
a decade, the role of the bioinformatician has often been
relegated to that of data analyst, librarian, database
manager, distribution specialist, or software engineer. Occa-
sionally, with introductions made early enough, bioinforma-
ticians have been included in the early design phases of
experiments, and their role noted as such on manuscripts
and publications. These engineering and infrastructure
roles, although important, evolved under the assumption
that the scientists making these measurements already know
good questions to ask but lack the specific skills to analyze,
store, retrieve, and disseminate their data. Engineering roles
in bioinformatics are important and are reasonably well
funded today (such as in the Cancer Bioinformatics Grid
(caBIG), Bioinformatics Research Network (BIRN), and the
National Centers for Biomedical Computing (NCBC), all in
the United States).
But considering and funding solely the engineering roles in
bioinformatics understates the potential function of
bioinformaticians as scientists - here defined as those who
come up with questions - and, even more importantly, it
limits the vision for bioinformaticians to ask questions that
no other scientists can ask or answer today. It has become
increasingly rare for the bioinformatician to take the role of
questioner, especially with regard to research that has an
impact on medical care or research that yields tools for
clinicians or patients. Here, I argue that the next steps
needed for the field of bioinformatics are a shift in role
towards asking questions and a shift in focus to medicine.
The field of translational bioinformatics, defined as ‘…the
development of storage, analytic and interpretive methods to
optimize the transformation of increasingly voluminous
biomedical data into proactive, predictive, preventative, and
participatory health’ [6], is the mechanism for this shift. I
outline below four reasons why bioinformaticians are newly
enabled to drive the questions in primary medical discovery,
and provide four recommendations for bioinformaticians
who would like to get more involved in translational
research.F Fo ou ur r   e en na ab bl li in ng g   o op pp po or rt tu un ni it ti ie es s
The most revolutionary force in translational bioinformatics
is the public availability of molecular data. Sharing data is
not new; large epidemiological datasets and DNA sequences
have been shared in various forms for several decades, even
before the internet era. In addition, the use of previously
published data is not new; the biostatistics literature is full
of novel methodology applied to well known datasets. But
instead of using public data to just improve one’s metho-
dology (for example, to build yet another classifier on Todd
Golub’s leukemia data [7]), or in basic science (for example,
to build yet another predictor for transcription factor bind-
ing sites), such data can now be used to enable new
questions in applied sciences.
Coupled with the public availability of molecular measure-
ment data is the promising capability of intersecting across
multiple experiments. At the time of writing, the National
Center for Biotechnology Information (NCBI) Gene Expres-
sion Omnibus (GEO) contains data from over 307,000
microarrays, from 12,100 independent experiments [8].
Although the growth rate has been exponential, GEO can be
currently described as having made available roughly 100
new microarrays each day since its launch in January 2001.
Imagine: a high school student today who needs to run a
science fair project can type ‘breast cancer’ at the NCBI GEO
home page to find data from nearly 400 experiments
totaling 24,200 samples, as easily as she can find songs on
iTunes. With the right tools, she could even discover the
‘common denominator’ across tens or hundreds of models of
breast cancer. Rhodes et al. [9] used this approach to
compile publicly available published microarray datasets in
which cancer samples were compared with appropriate
normal samples to find common changes in gene expression
across cancers, such as cell cycle genes involved in meta-
stasis, and my colleague and I [10] used 49 publicly available
gene expression, proteomics, and RNA interference datasets
to predict novel variants associated with obesity. Although
there are challenges in using this approach [11], with over
30% of the human-disease morbidity already represented in
GEO [12] there is clearly power in large numbers.
A negative disruptive factor, potentially steering bioinfor-
maticians away from staid approaches, has been the
increasing commoditization of bioinformatics methodology.
Over 1,100 databases are now listed in the Annual Database
issue of Nucleic Acids Research [13], with another hundred
web-servers listed separately [14]. Approximately 60 manu-
scripts are published each month describing software or
methodology in bioinformatics in the journals Genome
Biology, BMC Bioinformatics, BMC Genomics, and Bioin-
formatics. Even sophisticated choices on the best machine-
learning algorithm to use in a particular context have been
made trivial by free tools such as Weka [15], which
essentially abstract away the need to know specific
methodology. It is getting progressively harder to argue that
increasing sophistication and knowledge of this type of
methodology significantly improves one’s results.
With the availability of enormous sets of data and the
commoditization of methodology, merely making lists of
potential biomarkers and causal factors will eventually lose
value and significance. Although much additional value
comes from validation in real human samples, these samples
have typically been difficult to obtain, until now. Figure 1
shows one example out of many websites that now offer
human samples, antibodies that can be used to stain those
samples, and pathology services that can be used to read the
results. One can always question the reliability and quality of
these samples and services, as one can question samples and
services within one’s own institution. However, it is difficult
to ignore the importance of having these facilities available
to the bioinformatician. Although caveats must be acknow-
ledged, in many ways all that is now left to do is to ask the
interesting question.
F Fo ou ur r   r re ec co om mm me en nd da at ti io on ns s
How can the field of bioinformatics successfully adapt to the
translational movement? First, if the hardest part to scien-
tific endeavors in biomedical informatics is to ask the right
question, then investigators in biomedical informatics need
to learn more about open problems in medicine. Some of
this learning will come from non-traditional sources, such as
medical or surgical grand rounds (regular conferences
discussing the science around particularly challenging or
instructive cases) in a medical center. Often, ‘domain-
specific learning’ is viewed as a slippery slope; informa-
ticians sometimes retort that it is not possible to gain
competence across all areas of medicine while retaining
http://genomemedicine.com/content/1/6/64 Genome Medicine 2009, Volume 1, Issue 6, Article 64 Butte 64.2
Genome Medicine 2009, 1 1: :64
F Fi ig gu ur re e   1 1
Screenshot from US Biomax [19] showing a tissue microarray for sale
with 101 cases of pancreatic cancer or adjacent normal tissues. This figure
is representative of many other available companies offering products and
services for validation. Other such services can be found by searching the
internet with terms such as ‘tissue microarray’, ‘tissue samples’, and
‘serum samples’.expertise in a computational discipline. But learning about
the unaddressed challenges even in one particular area of
medicine is still better than knowing little or nothing about
any area of medicine; as most physician scientists know,
focus in one particular medical area of interest provides
more than enough challenges for a career. As informatics
tools become more easily accessible, understood, and used
without assistance by medical researchers, the reverse also
has to occur, with medical problems becoming understood
and addressed by computational investigators.
The corollary to this point is a second recommendation
directed towards bioinformaticians: with the commoditiza-
tion of bioinformatics methodologies, researchers in
informatics should not just build tools, they should be the
first to use them, even on publicly available data. Indeed, no
other investigator knows those tools better than the
inventor. Those who build tools to address a specific medical
question can and should report on both their tool and their
findings. After tools and methods have been shown to
answer one question particularly well, they can then be
generalized for additional questions. This recommendation
is contrary to the usual practice of building tools in bio-
informatics to enable others. In general, this will mean that
tools that have successfully enabled their creator to discover
an important finding should be viewed with higher regard,
as opposed to tools presenting a fancier user interface or
marginal gains in performance.
It is often easiest to criticize the quality of publicly available
resources, whether these resources are data or tools. Many
initiatives within the community of biomedical informatics
have tried to add value to these public resources by creating
standardized annotations (and metadata), catalogs, struc-
tured vocabularies, and ontologies, which can be used to
store, index, and retrieve them more efficiently and effec-
tively [16,17]. Although these efforts have the best of
intentions, we have to ensure that, in the push to improve
the quality of metadata, we do not inadvertently cause a
delay in the release of data or tools.
The final recommendation is for informaticians to broadly
consider their sources for molecular data. A tertiary care
academic medical center might see tens to hundreds of
thousands of patients with injuries and diseases each year.
In modern hospitals, nearly every intervention applied to
these patients is electronically recorded, and hundreds of
thousands of blood measurements are made yearly, along
with high-resolution images and tissue pathology. The scale
of the clinical enterprise easily dwarfs the abilities of most
typical animal model facilities, and the requirements for
quality assurance for medical measurements greatly exceeds
the typical levels of rigor applied in model experimentation.
Put another way, the typical clinical laboratory measurement
is much more believable than the typical spot on a micro-
array. There are barriers to accessing clinical data, but as
these can be overcome, bioinformaticians should start
considering humans as the ultimate model organism [18].
C Co on nc cl lu us si io on ns s
It is remarkable that in the decade or two since their
creation, high-throughput molecular measurements, such as
microarrays, have already been used to study so many
human diseases, and that data from these experiments are
publicly available. Representing so many diseases by
molecular measurements in gene expression (and other
measurement modalities in the future) brings us closer to a
consideration of the nature of disease itself. As the
community of biomedical informaticians is increasingly
involved (and funded) in the construction of infrastructure
and policies to gather and consolidate clinical and experi-
mental data, we have to consider that this community will
also be the prime user of these tools and techniques. Those
who apply their research to publicly available data, commo-
ditized tools, and streamlined paths through validation will
be able to create novel diagnostics and discover fundamental
causes of disease as targets for therapies. Investigators
empowered by methodologies in bioinformatics have never
been so well positioned to take on the role of translational
scientist, to build the tools to ask the questions that yield
discoveries to improve human health.
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